Ignite Creation Date:
2024-05-05 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00353574
Status:
TERMINATED
Last Update Posted:
2014-03-18
First Post:
2006-07-17
Brief Title:
DORADO-EX Long-Term Safety Extension Study to the Phase 3 DORADO Study Protocol DAR-311 of Darusentan in Resistant Hypertension
Sponsor:
Gilead Sciences
Organization:
Gilead Sciences
Study Overview
Official Title:
DORADO-EX - A Dose-Blinded Long-Term Safety Extension Study of Fixed Doses of Darusentan in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs Including a Diuretic Protocol DAR-311-E
Status:
TERMINATED
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study DAR-312 did not meet primary co-endpoints
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Darusentan
Brief Summary:
This is a research study of a new experimental drug called darusentan Darusentan is not currently approved by the United States US Food and Drug Administration FDA for use in the US which means that a doctor cannot prescribe this drug The purpose of this study is to evaluate the long-term safety of darusentan in subjects with resistant systolic hypertension despite treatment with full doses of three or more antihypertensive medications including a diuretic
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None